School of Acupuncture and Tuina, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Department of Ophthalmology, Third Military Medical University Southwest Hospital, Chongqing, China.
BMJ Open. 2023 Jun 19;13(6):e071864. doi: 10.1136/bmjopen-2023-071864.
Protracted opioid abstinence syndrome (POAS) refers to a series of physical discomforts and neuropsychiatric symptoms after discontinuation of opioid-type substances for a certain amount of time and is one of the main causes of relapse. Studies have shown that acupuncture is effective in the treatment of POAS. We plan to conduct this systematic review and meta-analysis to assess the efficacy and safety of acupuncture for POAS.
A comprehensive search of studies will be carried out in the following databases from inception to 31 January 2023: Web of Science, Embase, PubMed, Chinese Biology Medicine, China National Knowledge Infrastructure, Wan Fang Database and Chinese Scientific Journal Database (VIP). WHO International Clinical Trials Registry Platform, ClinicalTrials.gov and Chinese Clinical Trial Registry will also be searched for ongoing relevant trials, and 'grey literatures' will be identified from GreyNet International, OpenGrey and Google Scholar. Randomised controlled trials regarding acupuncture therapy for treatment of POAS will be included. The primary outcome is the severity of protracted withdrawal symptoms. Two reviewers will screen studies using the inclusion criteria, extract data and assess the risk of bias, respectively. The quality of evidence will be assessed using the Grading of Recommendations, Assessment, Development and Evaluation. Data synthesis will be performed using RevMan V.5.4.1.
This study will not invade patients' personal privacy, and so ethical review is not required. The results will be disseminated in a peer-reviewed journal.
CRD42022382978.
迁延性阿片类戒断综合征（POAS）是指在停止使用阿片类物质一定时间后出现的一系列身体不适和神经精神症状，是复吸的主要原因之一。研究表明，针刺在 POAS 的治疗中有效。我们计划进行这项系统评价和荟萃分析，以评估针刺治疗 POAS 的疗效和安全性。
从成立到 2023 年 1 月 31 日，我们将在以下数据库中全面搜索研究：Web of Science、Embase、PubMed、中国生物医学文献数据库、中国国家知识基础设施、万方数据库和中国科学期刊数据库（VIP）。还将在世界卫生组织国际临床试验注册平台、ClinicalTrials.gov 和中国临床试验注册中心搜索正在进行的相关试验，并从 GreyNet International、OpenGrey 和 Google Scholar 中确定“灰色文献”。将纳入关于针刺治疗 POAS 的随机对照试验。主要结局是迁延性戒断症状的严重程度。两名评审员将根据纳入标准筛选研究，分别提取数据并评估偏倚风险。使用推荐、评估、开发和评估分级法评估证据质量。使用 RevMan V.5.4.1 进行数据分析综合。
本研究不会侵犯患者的个人隐私，因此不需要伦理审查。研究结果将在同行评议的期刊上发表。
PROSPERO 注册号：CRD42022382978。
